Keyphrases
4-phase
40%
Abnormal Liver Tests
20%
Acute Renal Failure
20%
Acute Toxicity
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
B Cells
40%
Cardiomyopathy
20%
Cell-to-cell
20%
Cellular Products
20%
Chronic Active Hepatitis
20%
Chronic Toxicity
20%
Cyclophosphamide
20%
Cytopenia
20%
Cytoreduction
20%
Diffuse Large Cell
20%
Efficacy Data
20%
Etoposide
20%
Event-free Survival
20%
First Complete Remission
20%
Gradient Separation
20%
Granulocyte Colony-stimulating Factor (G-CSF)
40%
Hematopoietic Cells
20%
Hematopoietic Stem Cell Mobilization
20%
Hemorrhagic Cystitis
20%
Hepatitis C
20%
High Dose
100%
High Risk
20%
Histology
20%
Infectious Complications
20%
Leucovorin Rescue
20%
Leukapheresis
20%
Melphalan
20%
Methotrexate
20%
Mitoxantrone
20%
Monoclonal Antibody Panel
20%
Non-Hodgkin Lymphoma
100%
Overall Survival
20%
Partial Remission
20%
Percoll Gradient
20%
Peripheral T Cells
20%
Preparative Regimen
20%
Progressive Disease
20%
Remission Status
20%
Salvage Therapy
20%
Sequential Chemotherapy
100%
T Cells
40%
Toxicity Profile
20%
Transplant Recipients
40%
Treatment Toxicity
20%
Treatment-related Mortality
20%
White Blood Cells
20%
Medicine and Dentistry
Acute Kidney Injury
14%
B Cell
28%
Cell Transplantation
100%
Chemotherapy
100%
Chronic Active Hepatitis
14%
Chronic Toxicity
14%
Cyclophosphamide
14%
Cytopenia
14%
Disease
14%
Drug Megadose
100%
Etoposide
14%
Event Free Survival
14%
Factor V
14%
Folinic Acid
14%
Granulocyte Colony Stimulating Factor
28%
Hematopoietic Cell
100%
Hemorrhagic Cystitis
14%
Hepatitis C
14%
Infectious Complication
14%
Large Cell
14%
Leukapheresis
14%
Leukocyte
14%
Liver Function Test
14%
Melphalan
14%
Methotrexate
14%
Mitoxantrone
14%
Monoclonal Antibody
14%
Myocardial Disease
14%
Non-Hodgkin Lymphoma
100%
Overall Survival
14%
Progressive Disease
14%
Salvage Therapy
14%
T Cell
42%
Transplantation
28%
Vincristine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
25%
Blood Clotting Factor 5
25%
Chemotherapy
100%
Chronic Active Hepatitis
25%
Chronic Toxicity
25%
Cyclophosphamide
25%
Cytopenia
25%
Disease
50%
Etoposide
25%
Event Free Survival
25%
Folinic Acid
25%
Granulocyte Colony Stimulating Factor
50%
Hemorrhagic Cystitis
25%
Hepatitis C
25%
Infectious Complication
25%
Melphalan
25%
Methotrexate
25%
Mitoxantrone
25%
Monoclonal Antibody
25%
Myocardial Disease
25%
Nonhodgkin Lymphoma
100%
Overall Survival
25%
Remission
75%
Vincristine
25%
Immunology and Microbiology
B Cell
28%
Cell Transplantation
100%
Cyclophosphamide
14%
Drug Megadose
100%
Event Free Survival
14%
Granulocyte Colony-Stimulating Factor
28%
Hematopoietic Cell
100%
Hepatitis C
14%
Leukapheresis
14%
Leukocyte
14%
Liver Function
14%
Methotrexate
14%
Monoclonal Antibody
14%
Overall Survival
14%
T Cell
42%